Nota Informativa Importante su Dacogen (decitabina) (04/09/2017)
L'Agenzia Italiana del Farmaco rende disponibili nuove modifiche delle istruzioni per la diluizione della soluzione ricostituita di Dacogen (decitabina).
Italiano
L'Agenzia Italiana del Farmaco rende disponibili nuove modifiche delle istruzioni per la diluizione della soluzione ricostituita di Dacogen (decitabina).
The use of these alcohol pads and antiseptic towelettes could cause infections.
An extreme and unexpected reduction in dose than expected could lead to a delay in treatment, disruption of clinical care of the patient, and worsening of patient's conditions.
Risks associated with the use of Keytruda in combination with dexamethasone and an immunomodulatory agent (lenalidomide or pomalidomide) for the treatment of patients with multiple myeloma.
If administered to a patient, particulate may result in phlebitis, end-organ granuloma or micro-embolic effects, or gastrointestinal trauma.
Contaminated products with Burkholderia cepacia can potentially result in serious infections, may be life-threating in patients with compromised immune systems.
There is a reasonable probability of the following side effects of topical steroids which include but are not limited to skin changes, adrenal suppression, glaucoma, and cataracts.
FDA continues to recommend the use of thermoregulating devices (including forced air thermal regulating systems) for surgical procedures when clinically warranted.
Vulnerabilities, if exploited, could allow an unauthorized user to access patient's device, which could result in patient harm from rapid battery depletion or administration of inappropriate pacing.
L'Agenzia Italiana del Farmaco rende disponibili informazioni su una nuova formulazione di FLOLAN (con solvente a pH
12) che sarà disponibile a partire da settembre 2017, con notevoli differenze nelle
modalità di conservazione e somministrazione rispetto all’attuale formulazione
(con solvente a pH 10,5).
80.211.154.110